Selexipag for the Treatment of Pulmonary Arterial Hypertension

Expert Opinion on Pharmacotherapy - United Kingdom
doi 10.1517/14656566.2014.876007
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa Healthcare

Related search

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2016English

New Treatment Options for Pulmonary Arterial Hypertension — The First Selective IP-receptor Agonist Selexipag

Cardiovascular Therapy and Prevention (Russian Federation)
Cardiovascular MedicineCardiology
2019English

Future Perspectives for the Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2009English

Surgical Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2010English

Determining the Value Contribution of Selexipag for the Treatment of Pulmonary Arterial Hypertension (PAH) in Spain Using Reflective Multi-Criteria Decision Analysis (MCDA)

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2018English

Inhaled Iloprost for Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2002English

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Improving Outcomes

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2013English

Treatment of Pulmonary Arterial Hypertension in Pregnancy

American Journal of Health-System Pharmacy
MedicineHealth PolicyPharmacologyPharmacy
2007English

Epoprostenol Treatment for Idiopathic Pulmonary Arterial Hypertension in Pregnancy

Journal of Perinatology
GynecologyChild HealthPediatricsPerinatologyObstetrics
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy